What Is Altimmune, Inc. (ALT) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Altimmune, Inc.'s intrinsic value is estimated at $1.11, suggesting the stock is overvalued at its current price of $2.99. With 8 out of 9 models flagging downside (-63.0% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $2.91 (-2.7%), while ML-RIV — the most conservative — estimates $0.10 (-96.6%). This +93.9% gap reflects genuine analytical uncertainty about Altimmune, Inc.'s intrinsic worth.
What Do the Models Say About ALT?
9 of 13 models are currently active for ALT. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates ALT's intrinsic value at $1.45, implying -51.6% downside from the current price. See which stocks rank higher →
How Does ALT Rank in Biotechnology?
Among 62 Biotechnology stocks, ALT ranks #27 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.
See all Most Undervalued Biotechnology Stocks →
As a biotech sector, Altimmune, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating ALT should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ALT a Value Trap?
CirclFi's Value Trap algorithm assigns ALT a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Altimmune, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Altimmune, Inc. is rated at 5.1/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +93.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ALT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ALT's 9 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad